.png){kind=icon}
.png){kind=icon}
Return
Targeting HER2 in urothelial carcinoma: from pathway inhibition to antibody–drug conjugates
.png){kind=icon}
OA
AI
H
N
M
M
J
A
D
Z
S
R
DOI：10.1016/j.ctrv.2026.103173.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• HER2 expression in UC is heterogeneous and varies across histological subtypes. • Improved and standardized HER2 testing and biomarker strategies are urgently needed. • Conventional HER2 inhibition shows limited efficacy in urothelial carcinoma. • HER2-directed ADCs demonstrate significant activity in advanced disease. • Clinical benefit of HER2-directed ADCs extends beyond HER2-high to HER2-low tumors.
Keywords:
Bladder cancer
HER2
Urothelial cancer
IHC
Antibody-drug conjugates
Trastuzumab deruxtecan
Disitamab vedotin
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
10.5
Papers:
2.8K
Citations:
1.3W
Organization
Cited Papers